John Demaree - Net Worth and Insider Trading
John Demaree Net Worth
The estimated net worth of John Demaree is at least $44,271 dollars as of 2024-11-13. John Demaree is the Chief Commercial Officer of G1 Therapeutics Inc and owns about 5,250 shares of G1 Therapeutics Inc (GTHX) stock worth over $37,538. John Demaree is also the Chief Commercial Officer of Karyopharm Therapeutics Inc and owns about 7,500 shares of Karyopharm Therapeutics Inc (KPTI) stock worth over $6,734. Details can be seen in John Demaree's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Demaree has not made any transactions after 2020-08-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Demaree
John Demaree Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Demaree owns 2 companies in total, including Karyopharm Therapeutics Inc (KPTI) , and G1 Therapeutics Inc (GTHX) .
Click here to see the complete history of John Demaree’s form 4 insider trades.
Insider Ownership Summary of John Demaree
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc | 2020-08-26 | Chief Commercial Officer |
| GTHX | G1 Therapeutics Inc | 2018-12-10 | Chief Commercial Officer |
John Demaree Latest Holdings Summary
John Demaree currently owns a total of 2 stocks. Among these stocks, John Demaree owns 5,250 shares of G1 Therapeutics Inc (GTHX) as of December 10, 2018, with a value of $37,538 and a weighting of 84.79%. John Demaree also owns 7,500 shares of Karyopharm Therapeutics Inc (KPTI) as of August 26, 2020, with a value of $6,734 and a weighting of 15.21%.
Latest Holdings of John Demaree
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GTHX | G1 Therapeutics Inc | 2018-12-10 | 5,250 | 7.15 | 37,538 |
| KPTI | Karyopharm Therapeutics Inc | 2020-08-26 | 7,500 | 0.90 | 6,734 |
Holding Weightings of John Demaree
John Demaree Form 4 Trading Tracker
According to the SEC Form 4 filings, John Demaree has made a total of 0 transactions in G1 Therapeutics Inc (GTHX) over the past 5 years. The most-recent trade in G1 Therapeutics Inc is the acquisition of 1,000 shares on December 10, 2018, which cost John Demaree around $33,150.
According to the SEC Form 4 filings, John Demaree has made a total of 1 transactions in Karyopharm Therapeutics Inc (KPTI) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Karyopharm Therapeutics Inc is the acquisition of 7,500 shares on August 26, 2020, which cost John Demaree around $109,050.
Insider Trading History of John Demaree
- 1
John Demaree Trading Performance
GuruFocus tracks the stock performance after each of John Demaree's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Demaree is -22.3%. GuruFocus also compares John Demaree's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Demaree within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Demaree's insider trading performs compared to the benchmark.
Performance of John Demaree
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -17.39 | | | | | |
| Relative Return to S&P 500(%) | -14.02 | | | | | |
John Demaree Ownership Network
Ownership Network List of John Demaree
Ownership Network Relation of John Demaree
John Demaree Owned Company Details
What does Karyopharm Therapeutics Inc do?
Who are the key executives at Karyopharm Therapeutics Inc?
John Demaree is the Chief Commercial Officer of Karyopharm Therapeutics Inc. Other key executives at Karyopharm Therapeutics Inc include director & President and CEO Richard A. Paulson , EVP & CFO & Treasurer Michael Mason , and SVP Sales & Commercial Ops Sohanya Roshan Cheng .
Karyopharm Therapeutics Inc (KPTI) Insider Trades Summary
Over the past 18 months, John Demaree made no insider transaction in Karyopharm Therapeutics Inc (KPTI). Other recent insider transactions involving Karyopharm Therapeutics Inc (KPTI) include a net sale of 165,682 shares made by Richard A. Paulson , a net sale of 55,845 shares made by Michael Mason , and a net sale of 41,559 shares made by Sohanya Roshan Cheng .
In summary, during the past 3 months, insiders sold 27,326 shares of Karyopharm Therapeutics Inc (KPTI) in total and bought 0 shares, with a net sale of 27,326 shares. During the past 18 months, 2,078,182 shares of Karyopharm Therapeutics Inc (KPTI) were sold and 41,140 shares were bought by its insiders, resulting in a net sale of 2,037,042 shares.
Karyopharm Therapeutics Inc (KPTI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Karyopharm Therapeutics Inc Insider Transactions
John Demaree Mailing Address
Above is the net worth, insider trading, and ownership report for John Demaree. You might contact John Demaree via mailing address: 79 Tw Alexander Drive, 4501 Research Commons, Suite 100, Research Triangle Park Nc 27709.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
